相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Polymer Nanoparticles Mediated Codelivery of AntimiR-10b and AntimiR-21 for Achieving Triple Negative Breast Cancer Therapy
Rammohan Devulapally et al.
ACS NANO (2015)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells
Rammohan Devulapally et al.
MOLECULAR PHARMACEUTICS (2015)
Polymer nanoparticles for drug and small silencing RNA delivery to treat cancers of different phenotypes
Rammohan Devulapally et al.
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY (2014)
Integrated MicroRNA and mRNA Signatures Associated with Survival in Triple Negative Breast Cancer
Luciano Cascione et al.
PLOS ONE (2013)
Triple-negative breast cancer in the older population
P. Boyle
ANNALS OF ONCOLOGY (2012)
Adjuvant treatments for triple-negative breast cancers
H. Joensuu et al.
ANNALS OF ONCOLOGY (2012)
Neoadjuvant treatments for triple-negative breast cancer (TNBC)
G. von Minckwitz et al.
ANNALS OF ONCOLOGY (2012)
PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect
Sarbari Acharya et al.
ADVANCED DRUG DELIVERY REVIEWS (2011)
Therapeutic nanoparticles for drug delivery in cancer
Kwangjae Cho et al.
CLINICAL CANCER RESEARCH (2008)
Nanoparticles for drug delivery in cancer treatment
Barbara Haley et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2008)
Micellar nanocarriers: Pharmaceutical perspectives
V. P. Torchilin
PHARMACEUTICAL RESEARCH (2007)
The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays
Laura Smith et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Antitumoral actions of the anti-obesity drug orlistat (Xenical™) in breast cancer cells:: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene
JA Menendez et al.
ANNALS OF ONCOLOGY (2005)
Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids?
JA Menendez et al.
MEDICAL HYPOTHESES (2005)
Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity
SJ Kridel et al.
CANCER RESEARCH (2004)
Overexpression of fatty acid synthase in oesophageal squamous cell dysplasia and carcinoma
T Nemoto et al.
PATHOBIOLOGY (2001)
The expression of fatty acid synthase (FASE) is an early event in the development and progression of squamous cell carcinoma of the lung
CJ Piyathilake et al.
HUMAN PATHOLOGY (2000)
分享论文
